Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses corneal nerve loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease modification, pain severity, and functional capacity (6-minute walk test [6MWT]). Methods: Cibinetide (1, 4, or 8 mg/day) was compared to placebo. The primary study endpoint was a change in CNFA at 28 days. Results: The placebo-corrected mean change from baseline CNFA (μm2) at day 28 was 109 (95% confidence interval [CI], -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively. Intraepidermal GAP-43+ fibers increased in the 4 mg group (P = 0.035). Further, changes in CNFA correlated with changes in GAP-43+ (ρ = 0.575; P = 0.025) and 6MWT (ρ = 0.645; P = 0.009). Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group (P = 0.157). Conclusions: Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect. The relationships between CNFA and other clinical measures of disease support its use as a surrogate endpoint to assess potential disease modifying therapies for neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of the Neuropathic Pain Symptom Inventory
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., Rostaing, S., Lanteri-Minet, M., Collin, E., Grisart, J., et al. (2004) · Pain · doi:10.1016/j.pain.2003.12.024 · Cited by 1,329
Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study
Lauria, G., Bakkers, M., Schmitz, C., Lombardi, R., Penza, P., Devigili, G., Smith, A. G., Hsieh, S., Mellgren, S. I., Umapathi, T., et al. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00271.x · Cited by 518
Cited by
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
Self-citationDiabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“14 significantly increased small nerve fiber abundances in the cornea and skin, with improved neuropathic pain in patients with DPN(178) and sarcoid neuropathy.(179) Tanezumab is a fully humanized anti–nerve growth factor monoclonal antibody.”
BackgroundSelf-citationGrunewald, J., Grutters, J. C., Arkema, E. V., Saketkoo, L. A., Moller, D. R., & Müller-Quernheim, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0096-x · Cited by 479
Williams, B. M., Borroni, D., Liu, R., Zhao, Y., Zhang, J., Lim, J., Ma, B., Romano, V., Qi, H., Ferdousi, M., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05023-4 · Cited by 155
“CCM also predicts incident neuropathy [17] and accurately detects CNF regeneration [18, 50].”
BackgroundSelf-citationSmall fiber neuropathy: diagnosis, causes, and treatment
Sène, D. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.11.002 · Cited by 113
Metadata
- Authors
- Culver, D. A., Dahan, A., Bajorunas, D., Jeziorska, M., van Velzen, M., Aarts, L. P. H. J., Tavee, J., Tannemaat, M. R., Dunne, A. N., Kirk, R. I., Petropoulos, I. N., Cerami, A., Malik, R. A., & Brines, M.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-05-05
- Volume
- 58
- Issue
- 6
- Pages
- BIO52
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2611350664
- Cited by
- 104
- References
- 2
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.